| Anticonvulsant efficiency of sodium valproate conjugated with albumin nanoparticles in epileptic rat model |
| Paper ID : 1003-ISCH |
| Authors |
|
Mona Mohamed El-hefnawy *1, Rami B. Kassab2, Rizk Abd El-Moneim Rizk1, Magdy Mohamed Khalil3 1Department of Physics, Faculty of Science, Helwan University, Cairo, Egypt 2Department of Zoology, Faculty of Science, Helwan University, Cairo, Egypt 3School of Applied Health Sciences, Badr University in Cairo (BUC), Badr City and Department of Physics, Faculty of Science, Helwan University, Cairo, Egypt. |
| Abstract |
| Aim. Epilepsy is a chronic neurological disorder characterized by increased neuronal electrical activity and a spontaneous seizure. Several antiepileptic drugs are already available; however, their use is accompanied with unwanted side effects. Methods. The anticonvulsant actions of sodium valproate (VPA) with albumin nanoparticles (NPs) encapsulated sodium valproate (VPA) against an epileptic model caused by pentylenetetrazole (PTZ) was evaluated using different groups and injection doses. Results. The main results revealed that the prepared albumin nanoparticles showed a regular spherical shaped with a mean particle size 261.8 and 200.2 nm with and without drug loading, respectively, which was also confirmed by TEM image. Interestingly, sodium valproate loaded nanoparticles (VPANPs) showed a 90% entrapment efficiency with a 77% cumulative drug released for over 24 h, which is favourable to maintain drug within the therapeutic range after administration. Rats administered PTZ at a dose of 60 mg/kg exhibited a range of seizure activities, accompanied by an imbalance between the inhibitory neurotransmitter GABA and the excitatory amino acid glutamate in the hippocampus. Remarkably, both groups treated with free VPA (200 mg/kg) and VPANPs at dosages of 50 and 100 mg/kg for 14 consecutive days effectively delayed the onset of seizures and reduced the overall duration of convulsive episodes. Additionally, both treatments significantly increased GABA levels while decreasing glutamate levels. However, VPANPs demonstrated significantly greater efficacy compared to free VPA. Conclusion. These findings highlight the superior effectiveness of VPANPs in alleviating PTZ-induced seizures, suggesting a notable improvement over conventional VPA therapy in this experimental model. |
| Keywords |
| Albumin nanoparticles, Epilepsy, Antiepileptic drugs, Sodium valproate, Brain drug targeting |
| Status: Abstract Accepted (Poster Presentation) |